Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Accumulated Depreciation & Amortization: 2010-2025

Historic Accumulated Depreciation & Amortization for Northwest Biotherapeutics (NWBO) over the last 7 years, with Sep 2025 value amounting to $400,000.

  • Northwest Biotherapeutics' Accumulated Depreciation & Amortization changed negligibly% to $400,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $6.9 million, marking a year-over-year increase of 32.91%. This contributed to the annual value of $5.6 million for FY2024, which is 44.01% up from last year.
  • Per Northwest Biotherapeutics' latest filing, its Accumulated Depreciation & Amortization stood at $400,000 for Q3 2025, which was down 20.00% from $500,000 recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Accumulated Depreciation & Amortization ranged from a high of $5.6 million in Q4 2024 and a low of $400,000 during Q1 2024.
  • In the last 3 years, Northwest Biotherapeutics' Accumulated Depreciation & Amortization had a median value of $500,000 in 2025 and averaged $1.9 million.
  • Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first surged by 109.59% in 2022, then tumbled by 88.12% in 2024.
  • Northwest Biotherapeutics' Accumulated Depreciation & Amortization (Quarterly) stood at $1.1 million in 2021, then surged by 109.59% to $2.3 million in 2022, then spiked by 69.72% to $3.9 million in 2023, then spiked by 44.01% to $5.6 million in 2024, then remained steady at $400,000 in 2025.
  • Its Accumulated Depreciation & Amortization stands at $400,000 for Q3 2025, versus $500,000 for Q2 2025 and $400,000 for Q1 2025.